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ABSTRACT
Hypocomplementemic urticarial vasculitis syndrome (HUVS) is an uncommon small-vessel vasculitis presenting as a chronic urticaria with 
hypocomplementemia and the presence of anti-C1q autoantibodies. In most patients it is accompanied by a wide variety of extracutaneous 
manifestations such as arthritis, glomerulonephritis, ocular inflammation and pulmonary disease. We present a case of 49-year-old male 
with a 3-year history of recurrent urticaria accompanied by arthralgia, myalgia and gastrointestinal symptoms. The additional laboratory 
assessments revealed the presence of circulating anti-C1q autoantibodies in high titer. Histology of the lesional skin biopsy was consistent 
with leukocytoclastic vasculitis. The diagnosis of HUVS was confirmed in accordance to the currently adopted criteria. The described case 
emphasizes the necessity of high clinical suspicion when caring for patients with chronic urticaria and concomitant systemic symptoms.
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STRESZCZENIE
Pokrzywkowe zapalenie naczyń z hipokomplementemią (HUVS, hypocomplementemic urticarial vasculitis syndrome) to rzadko występujące 
zapalenie drobnych naczyń krwionośnych, którego objawami są przewlekła pokrzywka z hipokomplementemią oraz obecność przeciwciał 
anty-C1q. U większości chorych występuje również wiele objawów pozaskórnych, takich jak zapalenie stawów, kłębuszkowe zapalenie nerek, 
zmiany zapalne w obrębie oka i choroby płuc. W pracy przedstawiono przypadek 49-letniego pacjenta, u którego od 3 lat występowały 
nawracające epizody pokrzywki, którym towarzyszyły bóle stawów i mięśni oraz objawy żołądkowo-jelitowe. W badaniach laboratoryjnych 
wykazano wysokie miano krążących przeciwciał anty-C1q. Obraz histologiczny bioptatu skóry pobranego w obrębie zmian odpowiadał 
leukocytoklastycznemu zapaleniu naczyń. Rozpoznanie HUVS potwierdzono na podstawie obowiązujących obecnie kryteriów. Opisany 
przypadek zwraca uwagę, że przewlekła pokrzywka z objawami ogólnoustrojowymi powinna się wiązać z istotnym podejrzeniem klinicznym.
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Patient History
A 49-year-old white male presented to the dermatology 
unit with a 3-year history of arthralgia, myalgia and chro-
nic urticaria. Accompanying symptoms included a 4-week 
history of vomiting and diarrhea, a thirty-kilogram weight 
loss and significant pain and swelling of the interphalangeal 
joints of both hands and both knee joints.
The patient’s past medical history is noticeable for recur-
rent admissions to the internal medicine ward, where he was 
diagnosed with chronic gastritis, colitis and emphysema.
Skin examination revealed disseminated urticarial rash 
involving the trunk and the extremities (Fig. 1). The individu-
al lesions persisted for longer than 24 hours and were widely 
variable in size (Fig. 2). Physical examination was negative 
for any abnormalities except for the skin lesions described 
above and a decreased range of motion in the knee joints. 
Diagnostics 
Laboratory testing for systemic inflammation was po-
sitive with a markedly elevated C-reactive protein level of 
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Figure 1. Widespread urticarial rash on the upper body
Figure 2. Urticarial efflorescences in the lumbar region widely 
variable in size
49.9 mg/L (normal range: < 5.0 mg/L). Complete blood 
count was evident for a microcytic anemia with decreased 
serum iron concentration and low total iron binding ca-
pacity. Immunological analysis of serum was highly po-
sitive for anti-C1q autoantibodies at 193.9 U/mL (normal 
range: < 10 U/mL) and negative for p-ANCA (perinuclear 
anti-neutrophil cytoplasmic antibodies), c-ANCA (cytopla-
smic ANCA), ANA (antinuclear antibodies) and cryoglobu-
lins. C3 complement concentration was found to be de-
creased at 0.8 g/L (normal range: 0.9–1.8 g/L). Computed 
tomography of the lungs was evident for emphysema. Di-
rect immunofluorescence examination of the lesional skin 
Table 1. Criteria for diagnosis of HUVS (McDuffie’s criteria)* [3]
Symptoms/Abnormalities
Major Criteria Chronic urticaria > 6 months
Hypocomplementemia 





Positive anti-C1q autoantibodies with low C1q 
complement concentration in the serum
*The criteria fulfilled by the presented patient are in bold letters
sample reflected significant findings for IgA, IgM and IgG 
deposition in the walls of medium-caliber blood vessels, and 
C3c and C1q complement deposition in small- and medium-
-caliber blood vessels. In addition, C3c complement deposits 
were present along the epidermal basement membrane. 
PatHology
Histological examination of the lesional skin biopsy 
revealed weakly pronounced hyperkeratosis and acanthosis 
in the epidermis. The dermal layer showed dispersed epi-
dermotropic neutrophilic and eosinophilic infiltrate with 
a tendendcy to accumulate around the blood vessels (Fig. 3). 
The above-described histological picture was consistent 
with urticarial vasculitis.
Diagnosis anD treatment
The diagnosis of HUVS was confirmed by fulfilling 
McDuffie’s criteria. Table 1 highlights the symptoms and 
Figure 3. Histologic features demonstrating dispersed eosinophilic 
and neutrophilic infiltrate in the dermis showing a tendency to 
accumulate around blood vessels; the pattern is consistent with 
leukocytoclastic vasculitis (H&E stain at 20 × magnification)
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Table 2. Frequency and pattern of organ involvement in HUVS [3]
Involved organ Frequency of occurrence Symptoms 
Skin 100% Urticaria, angioedema, purpura, leukocytoclastic vasculitis
Joints 70% Arthralgia, arthritis
Kidneys 50% Proteinuria, hematuria, glomerulonephritis
Gastrointestinal tract 30% Abdominal pain, nausea, vomiting, diarrhea
Respiratory system 20% Decreased performance, cough, hemoptysis, chronic obstructive pulmonary disease
Eye 10% Conjunctivitis, episcleritis
Heart, Nervous system Rare Pericarditis, pseudotumor cerebri, meningitis
laboratory abnormalities that were present in our patient 
in order to meet the diagnostic criteria. The treatment with 
150 mg of dapsone daily in combination with 8 mg of me-
thylprednisolone daily was initiated leading to marked cli-
nical improvement.
Discussion
HUVS, or McDuffie syndrome, is defined as a small-vessel 
vasculitis characterized by recurrent urticarial lesions and 
hypocomplementemia with the frequent association of 
anti-C1q autoantibodies. The prevalence of HUVS is unk-
nown due to a relatively small number of only two hundred 
cases documented [1]. HUVS is eight times more prevalent 
in women than in men [1]. The disease onset may occur in 
childhood but majority of the patients seek medical atten-
tion during the fourth decade of life [1].
HUVS can be categorized into primary, or idiopathic, and 
secondary. The etiology of primary HUVS has not been yet 
established but there is evidence that both environmen-
tal and genetic factors are involved [1]; the contribution 
of genetic factors to the pathogenesis of HUVS may be 
hypothesized by the documented incidence of HUVS in 
siblings [1]. Secondary HUVS is most likely associated with 
a chronic disorder, frequently associated with systemic in-
flammation [2]. 
The classic presentation of HUVS includes episodic wi-
despread urticarial eruption on the face, trunk and pro-
ximal extremities that persists longer than 24 hours and 
usually resolves with hyperpigmentation. Histology of the 
lesional biopsy is consistent with leukocytoclastic vasculitis 
[3]. Systemic manifestations of the disease include fever, 
arthralgia, ocular inflammation and varied disturbances 
related to gastrointestinal, renal and pulmonary affection. 
Cutaneous lesions and arthralgia are the most frequent 
manifestations of HUVS (Tab. 2) [3]. Pulmonary symptoms 
include cough, dyspnea, pleural effusion and emphysema; 
chronic obstructive pulmonary disease is diagnosed in as 
many as 20–50% of patients presenting with HUVS [3]. About 
half of the patients present with renal disease commonly 
manifested by proteinuria and hematuria [3]. Ocular chan-
ges include conjunctivitis, uveitis and episcleritis [3]. Of 
note, HUVS may be associated with both Hodgkin’s and 
non-Hodgkin’s lymphomas, possibly due to the prolonged 
B-cell stimulation [2].
Typical laboratory abnormalities seen in HUVS individu-
als include an elevated erythrocyte sedimentation rate and 
low levels of C4, C1q, and sometimes also C3, complement 
components [3]. Leukocytoclastic vasculitis on histology is 
a frequent and helpful finding, however, not obligatory to 
establish the diagnosis [3]. 
The diagnostic criteria for HUVS, sometimes called 
McDuffie’s criteria, are divided into major and minor. The 
major criteria consist of urticaria persisting for longer 
than six months and hypocomplementemia. The minor 
criteria include positive histopathology, glomerulonephritis, 
arthralgia/arthritis, abdominal pain, ocular inflammation 
and positive anti-C1q autoantibody. Diagnosis requires the 
presence of both major criteria together with at least two 
minor criteria [3].
Treatment of HUVS is dependent on the disease severity, 
in particular on the presence of concomitant systemic symp-
toms. If the disease is limited to the skin, with no systemic 
involvement present, management with antihistamines is 
recommended [3]. HUVS with concomitant joint affection 
should be treated with low-dose prednisone in combination 
with immunosuppressive or immunomodulatory agents 
such as mycophenolate mofetil, methotrexate, azathiopri-
ne, cyclophosphamide, dapsone or hydroxychloroquine [3, 
4]. If HUVS is associated with glomerulonephritis or other 
potentially life-threatening systemic manifestations, im-
mediate treatment with high-dose glucocorticosteroids 
in combination with cytotoxic agent is required [4]. Future 
management with new monoclonal antibodies, such as 
canakinumab targeted at interleukin-1β, may change the 
treatment regimen for patients suffering from HUVS [5].
A relatively small number of HUVS cases has been do-
cumented so far. Kervarrec et al. [6] reported a 63-year-old 
female presenting with a chronic bullous urticaria, 10-ki-
logram weight loss, abdominal pain, pericardial effusion, 
hypocomplementemia, and the presence of anti-C1q auto-
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antibodies. This patient seemed to demonstrate some simi-
larities to our case report, such as unexplained weight loss, 
chronic urticaria and some laboratory abnormalities, but 
the contrast between the sex and pericardial involvement 
indicates the possibility of distinct systemic presentations 
of HUVS. Jachiet et al. [4] performed a retrospective study 
on efficacy of treatment in HUVS by measuring the time-
-to-treatment failure (TTF). Hydroxychloroquine, colchicine 
and glucocorticosteroids were established as a first-line 
therapy. Azathioprine, mycophenolate mofetil and cyc-
lophosphamide should be used in refractory cases. It 
is worth to point out that dapsone was not considered 
a first-line treatment modality due to lack of studies on 
the drug’s TTF. In contrast, Hérault et al. [7], Eiser et al. [8] 
and Nürnberg et al. [9] demonstrated considerable im-
provement of HUVS symptoms after dapsone treatment. 
Provided a favorable safety profile of dapsone, further 
research on this agent in the treatment of HUVS should 
be considered.
Multiple case reports confirm the tendency for occur-
rence of HUVS in the fourth decade of life [10, 11]. However, 
Al Mosawi et al. [12] and DeAmicis et al. [13] presented case 
reports of an 8-year-old boy and a 12-year-old girl with HUVS 
respectively, which exemplified the possible variability in 
the age of onset of the disease. 
conclusion
Since multiple systemic presentations of this rare condi-
tion exist, the presence of chronic urticaria and unexplained 
extracutaneous manifestations should prompt the suspicion 
of HUVS. In addition, due to its many similarities to systemic 
lupus erythematosus, the diagnosis of the latter should 
always be excluded.
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